- Source type
- Trial registry
- Access type
- Abstract/index
- Publisher
- PubMed
- Indexed by
- PubMed
- Date
- 2024
- Added
- 2026-06-19
Trust profile
91
Government health research
- Publisher type
- Government research
- Bias profile
- Low
Best used for
- Research synthesis
- Public-health context
- Safety resources
Weak for
- Primary endpoint extraction when a study is available
Used in Viral Vitalism
GLP-1s Are Not Just a Weight Loss Story
Roles: Background
Show section-level references
Claims supported
- Semaglutide has phase 3 MASH evidence and regulatory relevance for a defined noncirrhotic population with fibrosis.
Related studies
Related sources
ESSENCE clinical trial registry
ClinicalTrials.gov used across the Viral Vitalism evidence library.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 3 connections
FDA approves Wegovy for metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis
U.S. Food and Drug Administration used across the Viral Vitalism evidence library.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 6 connections
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
PubMed used across the Viral Vitalism evidence library.
- Trust score
- 91
- Publisher
- PubMed
- Indexed by
- PubMed
- Access
- Abstract/index
- Usage
- 4 connections
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder
Trial registry for oral semaglutide among adults with AUD.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
Does Semaglutide Reduce Alcohol Intake
Trial registry for semaglutide and alcohol intake.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
Effects of Semaglutide on Nicotine Intake
Trial registry for semaglutide and nicotine intake.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 2 connections
